TW200640466A - Method of treatment - Google Patents

Method of treatment

Info

Publication number
TW200640466A
TW200640466A TW095100687A TW95100687A TW200640466A TW 200640466 A TW200640466 A TW 200640466A TW 095100687 A TW095100687 A TW 095100687A TW 95100687 A TW95100687 A TW 95100687A TW 200640466 A TW200640466 A TW 200640466A
Authority
TW
Taiwan
Prior art keywords
related disorders
disorders
substance
pharmaceutically acceptable
limited
Prior art date
Application number
TW095100687A
Other languages
English (en)
Chinese (zh)
Inventor
Patricia C Davis
Jeffrey M Goldstein
Scott W Grimm
Helen R Winter
Raymond F Suckow
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200640466A publication Critical patent/TW200640466A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW095100687A 2005-01-07 2006-01-06 Method of treatment TW200640466A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64226205P 2005-01-07 2005-01-07
US73786405P 2005-11-18 2005-11-18
US73786505P 2005-11-18 2005-11-18
US73788705P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
TW200640466A true TW200640466A (en) 2006-12-01

Family

ID=36647771

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095100687A TW200640466A (en) 2005-01-07 2006-01-06 Method of treatment

Country Status (6)

Country Link
EP (1) EP1838325A1 (fr)
JP (1) JP2008526839A (fr)
AR (1) AR052191A1 (fr)
TW (1) TW200640466A (fr)
UY (1) UY29326A1 (fr)
WO (1) WO2006073360A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007062339A2 (fr) * 2005-11-18 2007-05-31 Astrazeneca Ab Formulations liquides
KR20110019781A (ko) * 2008-06-20 2011-02-28 아스트라제네카 아베 디벤조티아제핀 유도체 및 그의 용도
WO2010085976A1 (fr) * 2009-01-30 2010-08-05 F.I.S. Fabbrica Italiana Sintetici S.P.A. Procédé pour la synthèse de quétiapine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US7071133B2 (en) * 1993-11-16 2006-07-04 Ppg Industries Ohio, Inc. Colored glass compositions and-automotive vision panels with-reduced transmitted-color shift
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
SE0003126D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
ES2284830T3 (es) * 2001-02-06 2007-11-16 Astrazeneca Ab Uso de quetiapina para el tratamiento de la cocaina.
AU2003301253A1 (en) * 2002-10-18 2004-05-04 Massachusetts Mental Health Institute TREATING ALCOHOL AND OR SUBSTANCE ABUSE BY ANTAGONIZING Alpha 2 ADRENERGIC RECEPTORS WITH WEAK DOPAMINE BLOCKING
MXPA05013869A (es) * 2003-07-02 2006-02-28 Astrazeneca Ab Metabolito de quetiapina.
WO2005053619A2 (fr) * 2003-12-04 2005-06-16 The Research Foundation Of The City University Of New York Effets de la clozapine et de la cocaine sur la liberation de dopamine et de serotonine dans le noyau accumbens pendant un comportement psychostimulant et sevrage
WO2005063254A2 (fr) * 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Analogues de diaryl[a,d]cycloheptene amino substitues utilises comme agonistes muscariniques, et procedes de traitement de troubles neuropsychiatriques
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic

Also Published As

Publication number Publication date
EP1838325A1 (fr) 2007-10-03
AR052191A1 (es) 2007-03-07
WO2006073360A1 (fr) 2006-07-13
UY29326A1 (es) 2006-08-31
JP2008526839A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
WO2006060507A3 (fr) Procedes et compositions d'utilisation de composes immunomodulatoires pour le traitement des troubles d'immunodeficience
MA28469B1 (fr) Inhibiteurs de la dipeptidyle peptidase
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
DK1879873T3 (da) Neuroterapeutiske azolforbindelser
WO2007041365A3 (fr) Composes organiques
WO2004037169A3 (fr) Inhibiteurs de dipeptidylpeptidase heterocyclique beta-amino destines au traitement ou a la prevention de diabetes
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
GB0225474D0 (en) Therapeutic agents
TNSN06315A1 (en) Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
DE602004014361D1 (de) Verwendung von oxazolidinon-chinolin-hybrid-antibiotika zur behandlung von anthrax und anderen infektionen
GEP20105053B (en) Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
WO2006017673A3 (fr) Influence du taj sur les fonctions neuronales
WO2007006003A3 (fr) Combinaisons d'eszopiclone et de trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphtalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphtalenamine, et methodes de traitement de la menopause et des troubles de l'humeur, de l'anxiete et troubles cognitifs
TW200640466A (en) Method of treatment
MY142252A (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
WO2005075450A3 (fr) Nouveaux composes spiro-pentacycliques
EP2543384A3 (fr) Traitement des conditions impliquant la démyélinisation
DE602004015089D1 (de) Pyrroloimidazolderivate ,verfahern zu ihrer herstellung, diese enthaltende zusammensetzungen, und ihre verwendung als nootropika
DE60036122D1 (de) Verwendung von eplerenon zur behandlung von restenose
TW200616644A (en) Medicine for prevention or treatment of diabetes
TW200503726A (en) Use of dihydroimidazolones for the treatment of dogs
WO2021247916A8 (fr) Composés d'azétidine et de spiroazétidine et leurs utilisations
WO2005007239B1 (fr) Utilisation de la dapsone comme neuroprotecteur dans l'infarctus cerebral
DE60119742D1 (de) Methode zur behandlung der hyperaktiven blase
WO2008021432A3 (fr) Compositions et méthodes de traitement d'états affectant le système nerveux